(RTTNews) - eFFECTOR Therapeutics, Inc. and Pfizer Inc. (PFE) have entered a worldwide license and collaboration agreement to develop small-molecule inhibitors of eukaryotic initiation factor 4E, or eIF4E. eIF4E is a highly oncogenic and historically intractable target that is activated in a variety of human cancers.
"We look forward to working with eFFECTOR with the goal of bringing a promising new therapy to patients with various treatment-refractory cancers," said Jeff Settleman, senior vice president and chief scientific officer, oncology, worldwide research, development & medical, Pfizer.
eFFECTOR will receive a $15 million payment upfront, and will be eligible for additional potential $492 million in R&D funding, development and sales milestone payments. eFFECTOR will also receive royalties on sales of any products that may result from the collaboration.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
